Comparison between anti-VEGF therapy and corticosteroid or laser therapy for macular oedema secondary to retinal vein occlusion: A meta-analysis

Journal of Clinical Pharmacy and Therapeutics

Volumn 42, Issue 5, 2017, Pages 519-529

  Qian, T ^a   Zhao, M ^a   Xu, X ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

anti VEGF; dexamethasone; laser photocoagulation; retinal vein occlusion; triamcinolone

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CORTICOSTEROID; DEXAMETHASONE; RANIBIZUMAB; TRIAMCINOLONE; VASCULOTROPIN ANTIBODY; ANGIOGENESIS INHIBITOR; GLUCOCORTICOID; VASCULOTROPIN A;

BEST CORRECTED VISUAL ACUITY; BRANCH RETINAL VEIN OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; CENTRAL RETINAL THICKNESS; COMPARATIVE STUDY; DRUG EFFICACY; HUMAN; INTRAOCULAR PRESSURE; LASER COAGULATION; LOW RISK PATIENT; MACULAR EDEMA; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; COMPLICATION; LOW LEVEL LASER THERAPY; PROCEDURES; RETINA VEIN OCCLUSION; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; GLUCOCORTICOIDS; HUMANS; LASER THERAPY; MACULAR EDEMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETINAL VEIN OCCLUSION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 85021264746     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12551     Document Type: Review

References (40)

1. Hayreh SS, Zimmerman MB, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol. 1994;117:429-441.
2. Hatz K, Martinez M. Retinal vein occlusion: an interdisciplinary approach. Ther Umsch. 2016;73:85-89.
3. Rogers S, McIntosh RL, Cheung N, et al. International eye disease consortium: the prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117:313-319.
4. Wong TY, Scott IU. Retinal-vein occlusion. N Engl J Med. 2010;363:2135-2144.
5. Finkelstein D. Argon laser photocoagulation for macular edema in branch vein occlusion. Ophthalmology. 1986;93:975-977.
6. Parodi MB, Saviano S, Ravalico G. Grid laser treatment in macular branch retinal vein occlusion. Graefe's Arch Clin Exp Ophthalmol. 1999;237:1024-1027.
7. Laouri M, Chen E, Looman M, et al. The burden of disease of retinal vein occlusion: review of the literature. Eye. 2011;25:981-988.
8. Kriechbaum K, Michels S, Prager F, et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol. 2008;92:518-522.
9. Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 2012;119:802-809.
10. Zhang H, Liu ZL, Sun P, et al. Intravitreal bevacizumab for treatment of macular edema secondary to central retinal vein occlusion: eighteen-month results of a prospective trial. J Ocul Pharmacol Ther. 2011;27:615-621.
11. Brown DM, Heier JS, Clark WL, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol. 2013;155:429-437.
12. Song W, Xia X. Ranibizumab for macular edema secondary to retinal vein occlusion: a meta-analysis of dose effects and comparison with no anti-VEGF treatment. BMC Ophthalmol. 2015;15:31.
13. Lu Y, Su L, Xu X. Bevacizumab for macular edema secondary to retinal vein occlusion: a systematic review and meta-analysis. J Ocul Pharmacol Ther. 2013;29:702-708.
14. Lee K, Jung H, Sohn J. Comparison of injection of intravitreal drugs with standard care in macular edema secondary to branch retinal vein occlusion. Korean J Ophthalmol. 2014;28:19-25.
15. Novartis. Extension study to compare long-term efficacy and safety of ranibizumab intravitreal injections versus dexamethasone intravitreal implant in patients with RVO. https://clinicaltrials.gov/ct2/show/NCT01580020?term=NCT01580020.&rank=1. 2016. Accessed April 11, 2016.
16. ® in Patients With Branch Retinal Vein Occlusion. https://clinicaltrials.gov/ct2/show/NCT01427751?term=NCT01427751&rank=1. 2016. Accessed January 19, 2016.
17. Campochiaro PA, Clark WL, Boyer DS, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology. 2015;122:538-544.
18. Guignier B, Subilia-Guignier A, Fournier I, et al. Prospective pilot study: efficacy of intravitreal dexamethasone and bevacizumab injections in the treatment of macular oedema associated with branch retinal vein occlusion. Ophthalmologica. 2013;230:43-49.
19. Pielen A, Mirshahi A, Feltgen N, et al. Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six-month results of a prospective randomized clinical trial. Acta Ophthalmol. 2015;93:e29-e37.
20. Rehak M, Spies E, Scholz M, et al. Intravitreal treatment of patients with branch retinal vein occlusion depending on the duration of macular edema [German]. Der Ophthalmologe. 2013;110:966-974.
21. Russo V, Barone A, Conte E, et al. Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. Retina. 2009;29:511-515.
22. Tan MH, McAllister IL, Gillies ME, et al. Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion. Am J Ophthalmol. 2014;157:237-247.
23. Ding X, Li J, Hu X, et al. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion. Retina. 2011;31:838-845.
24. Gado AS, Macky TA. Dexamethasone intravitreous implant versus bevacizumab for central retinal vein occlusion-related macular oedema: a prospective randomized comparison. Clin Exp Ophthalmol. 2014;42:650-655.
25. Novartis. Efficacy and safety of ranibizumab intravitreal injections versus dexamethasone intravitreal implant in patients with central retinal vein occlusion (CRVO). https://www.clinicaltrials.gov/ct2/show/NCT01396083?term=NCT01396083&rank=1. 2015. Accessed September 19, 2016.
26. Ramezani A, Esfandiari H, Entezari M, et al. Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent onset central retinal vein occlusion. Acta Ophthalmol. 2014;92:e530-e539.
27. Korobelnik JF, Holz FG, Roider J, et al. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study. Ophthalmology. 2014;121:202-208.
28. Rhee DJ, Peck RE, Belmont J, et al. Intraocular pressure alterations following intravitreal triamcinolone acetonide. Br J Ophthalmol. 2006;90:999-1003.
29. Roth DB, Verma V, Realini T, et al. Long-term incidence and timing of intraocular hypertension after intravitreal triamcinolone acetonide injection. Ophthalmology. 2009;116:455-460.
30. ®) in its treatment. Graefe's Arch Clin Exp Ophthalmol. 2016;254:1257-1265.
31. Funk M, Kriechbaum K, Prager F, et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci. 2009;50:1025-1032.
32. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
33. Miller JW, Le Couter J, Strauss EC, et al. Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology. 2013;120:106-114.
34. Azad R, Vivek K, Sharma Y, et al. Ranibizumab as an adjunct to laser for macular edema secondary to branch retinal vein occlusion. Indian J Ophthalmol. 2012;60:263.
35. Azad SV, Salman A, Mahajan D, et al. Comparative evaluation between ranibizumab combined with laser and bevacizumab combined with laser versus laser alone for macular oedema secondary to branch retinal vein occlusion. Middle East Afr J Ophthalmol. 2014;21:296-301.
36. Çekiç O, Çakır M, Yazıcı AT, et al. A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion. Curr Eye Res. 2010;35:925-929.
37. Fan C, Wang Y, Ji Q, et al. Comparison of clinical efficacy of intravitreal ranibizumab with and without triamcinolone acetonide in macular edema secondary to central retinal vein occlusion. Curr Eye Res. 2014;39:938-943.
38. Moon J, Kim M, Sagong M. Combination therapy of intravitreal bevacizumab with single simultaneous posterior subtenon triamcinolone acetonide for macular edema due to branch retinal vein occlusion. Eye. 2016;30:1084-1090.
39. Donati S, Barosi P, Bianchi M, et al. Combined intravitreal bevacizumab and grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion. Eur J Ophthalmol. 2011;22:607-614.
40. Stefánsson E. The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology. Acta Ophthalmol Scand. 2001;79:435-440.